Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy

Benjamin Madden1, Raman Deep Singh2, Mark Haas3

  • 1Mayo Clinic Proteomics Core, Mayo Clinic, Rochester, Minnesota, USA.

Kidney International
|March 6, 2024
PubMed

Insights

Dense deposit disease (DDD), a form of C3 glomerulopathy (C3G), shows deposits enriched with apolipoprotein E (ApoE). ApoE staining may aid in diagnosing DDD, distinguishing it from C3 glomerulonephritis (C3GN).

Area of Science:

  • Nephrology
  • Complement biology
  • Pathology

Background:

  • C3 glomerulopathy (C3G) encompasses C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).
  • Both C3GN and DDD exhibit bright glomerular C3 staining but differ in electron microscopy findings.
  • DDD shows dense deposits, while C3GN deposits are not dense, with the underlying cause unknown.

Purpose of the Study:

  • To investigate the molecular differences in glomerular deposits between DDD and C3GN.
  • To identify potential biomarkers for distinguishing DDD from C3GN.

Main Methods:

  • Laser microdissection coupled with mass spectrometry (LCM/MS) was used on kidney biopsies from DDD, C3GN, and control cases.
  • Immunohistochemistry and confocal staining were performed for apolipoprotein E (ApoE).
  • Validation studies were conducted on a larger cohort of C3G cases.

Main Results:

  • Both DDD and C3GN showed increased complement proteins compared to controls.
  • DDD exhibited significantly higher levels of terminal complement pathway proteins (C5-9) and apolipoprotein E (ApoE) compared to C3GN.
  • ApoE staining strongly correlated with dense deposits in DDD, enabling diagnostic differentiation.

Conclusions:

  • Dense deposits in DDD are characterized by enrichment with apolipoprotein E (ApoE).
  • ApoE staining serves as a valuable adjunct to electron microscopy for diagnosing DDD.
  • ApoE detection offers a potential diagnostic tool for DDD, especially when electron microscopy is unavailable.